Background: Treatment regimens and prognoses of gastrointestinal stromal tumors (GIST) are quite different for tumors in different risk categories. Accurate preoperative grading of tumors is important for avoiding under- or overtreatment.
Purpose: To develop and validate an MRI texture-based model to predict the mitotic index and its risk classification.
Study Type: Retrospective.
Population: Ninety-one patients with histologically-confirmed GIST; 64 patients in a training cohort, and 27 patients in a test cohort.
Field Strength/sequence: T -weighted imaging (T WI), diffusion-weighted imaging (DWI), and dynamic contrast-enhanced three-dimensional volumetric interpolated breath-hold examination (3D-VIBE) at 1.5T.
Assessment: GIST images were manually segmented by two independent radiologists using ITK-SNAP software and MRI features were extracted using Pyradiomics. Two pathologists reviewed the tissue specimens of the tumors to identify the mitotic index and risk classification in consensus.
Statistical Tests: The least absolute shrinkage and selection operator (LASSO) regression method was used to select texture features. A logistic regression model was established based on the radiomic score (radscore), tumor location, and maximum diameter to predict tumor classification and develop a nomogram. Receiver operator characteristic (ROC) curves were used to evaluate the ability of the nomogram to distinguish between two tumors with different risk classifications, and a calibration curve was used to evaluate the consistency between the predicted risk and the actual risk.
Results: The texture signature achieved high efficacy in predicting the mitotic index area under the curve ([AUC], 0.906; 95% confidence interval [CI]: 0.813, 0.961). A nomogram for prediction of the risk classification of GIST, which incorporated this texture signature together with maximum tumor diameter and location, allowed good discrimination in the training cohort (AUC, 0.878; 95% CI: 0.769, 0.960) and the validation cohort (AUC, 0.903; 95% CI: 0.732, 0.922).
Data Conclusion: The texture-based model can be used to predict GIST mitotic index and risk classification preoperatively.
Level Of Evidence: 2.
Technical Efficacy Stage: 3.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jmri.27390 | DOI Listing |
Cureus
December 2024
Department of Medicine, ASEAB (Association for Socio-Economic Advancement of Bangladesh) Community Hospital and Diagnostic Center, Pabna, BGD.
Objective: Phyllodes tumor (PT) is a variant of fibroepithelial proliferations of the breast, histologically demonstrating a leaf-like pattern. The WHO has categorized PTs as benign, borderline, or malignant based on their histological characteristics. The objective of this paper is to assess the clinicopathological factors with malignancy in PT of the breast.
View Article and Find Full Text PDFBlood
January 2025
Umeå University, Department of Medical Biosciensces, Department of Clinical Microbiology, Umeå, Sweden.
Current intensive treatment of pediatric T-cell acute lymphoblastic leukemia (T-ALL) has substantial side-effects, highlighting a need for novel biomarkers to improve risk stratification. Canonical biomarkers such as genetics and immunophenotype are largely not used in pediatric T-ALL stratification. This study aimed to validate the prognostic relevance of DNA methylation CpG island methylator phenotype (CIMP) risk stratification in two pediatric T-ALL patient cohorts: the Nordic NOPHO ALL2008 T-ALL study cohort (n=192) and the Dutch DCOG ALL-10/ALL-11 validation cohorts (n=156).
View Article and Find Full Text PDFANZ J Surg
January 2025
Department of Surgery, Western Health, St. Albans, Victoria, Australia.
Background: Metformin is a diabetes medication with anti-mitotic properties. A narrative review was performed to investigate people using metformin and the risk of developing pancreatic ductal adenocarcinoma (PDAC) as well as survival outcomes in established PDAC.
Methods: Relevant studies on metformin use and PDAC were retrieved from PubMed including observational studies on metformin and the risk of developing PDAC and survival outcomes in PDAC, and randomized controlled trials of metformin as a treatment in PDAC.
Am J Transl Res
December 2024
Department of Medical Laboratory Technology, Medical College, Yangzhou Polytechnic College Yangzhou 225009, Jiangsu, PR China.
Objectives: In vitro experiments were manipulated to investigate the effect of the (PICALM-interacting mitotic regulator gene) expression level on the malignant phenotype of liver cancer cells and their tumorigenesis ability in nude mice, and bioinformatics were used to analyze the clinical diagnostic and prognostic value in liver cancer.
Methods: After liver cancer-related data were obtained from the TCGA database and GTEx database, the differences in expression in liver cancer and normal liver tissue were compared using bioinformatics, and their correlation with the clinical pathological characteristics of liver cancer and the prognosis value were analyzed. A knockdown and overexpression model of was constructed using Huh7 cells.
Immun Inflamm Dis
January 2025
Second Department of Oncology, Guangdong Second Provincial General Hospital, Guangzhou, China.
Background: SET domain-containing protein 4 (SETD4) is a histone methyltransferase that has been shown to modulate cell proliferation, differentiation, and inflammatory responses by regulating histone H4 trimethylation (H4K20me3). Previous reports have demonstrated its function in the quiescence of cancer stem cells as well as drug resistance in several cancers. A limited number of systematic studies have examined SETD4's role in the tumor microenvironment, pathogenesis, prognosis, and therapeutic response.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!